Clinical Research Directory

Inclusion Criteria: * Adults (≥18 years) * Be deemed eligible for buprenorphine treatment for OUD by the FQHC treatment provider and agree to engage in this treatment; * Not require an inpatient level of care as determined by the healthcare provider; * Be capable of providing valid contact information and informed consent; and * Permit the research team to use and disclose their protected health information (PHI). Exclusion Criteria: Individuals who are intoxicated, cognitively impaired, or psychiatrically unstable at baseline will not be included; however, they may subsequently be included if the disqualifying condition subsides. DSM 5 criteria for OUD include: * Taking opioids in larger amounts or longer than intended; * Failed efforts to quit or cut back; * Spending a lot of time obtaining the opioid; * Craving or urges to use; * Repeated inability to carry out major work, school, or home obligations; * Continued use despite persistent or recurring interpersonal problems worsened by opioid use; * Stopping or reducing important social, recreational activities due to opioid use; * Recurrent use of opioids in physically hazardous situations; * Continued opioid use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance; * Tolerance; and * Withdrawal. Moderate OUD severity is denoted by the presence of 4 or 5 of these symptoms and severe OUD is denoted by 6 or more symptoms. Patients will be excluded from the study if their SUD is primarily for a different substance, or their co-morbid psychiatric needs indicate enhanced needs.